JP2020515523A - ガン治療 - Google Patents

ガン治療 Download PDF

Info

Publication number
JP2020515523A
JP2020515523A JP2019541267A JP2019541267A JP2020515523A JP 2020515523 A JP2020515523 A JP 2020515523A JP 2019541267 A JP2019541267 A JP 2019541267A JP 2019541267 A JP2019541267 A JP 2019541267A JP 2020515523 A JP2020515523 A JP 2020515523A
Authority
JP
Japan
Prior art keywords
inhibitor
methyl
hydroxy
daily dose
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019541267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515523A5 (enExample
Inventor
デービス，ポール・フランク
イティンテアング，ティンテ
マーシュ，レジナルド・ウォルター
タン，スウィー・トング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gillies Mcindoe Research Institute
Original Assignee
Gillies Mcindoe Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gillies Mcindoe Research Institute filed Critical Gillies Mcindoe Research Institute
Publication of JP2020515523A publication Critical patent/JP2020515523A/ja
Publication of JP2020515523A5 publication Critical patent/JP2020515523A5/ja
Priority to JP2023039476A priority Critical patent/JP2023075272A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019541267A 2017-01-31 2018-01-31 ガン治療 Pending JP2020515523A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023039476A JP2023075272A (ja) 2017-01-31 2023-03-14 ガン治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762452479P 2017-01-31 2017-01-31
US62/452,479 2017-01-31
PCT/NZ2018/050006 WO2018143826A1 (en) 2017-01-31 2018-01-31 Cancer therapeutic

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023039476A Division JP2023075272A (ja) 2017-01-31 2023-03-14 ガン治療

Publications (2)

Publication Number Publication Date
JP2020515523A true JP2020515523A (ja) 2020-05-28
JP2020515523A5 JP2020515523A5 (enExample) 2021-03-11

Family

ID=63040946

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019541267A Pending JP2020515523A (ja) 2017-01-31 2018-01-31 ガン治療
JP2023039476A Pending JP2023075272A (ja) 2017-01-31 2023-03-14 ガン治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023039476A Pending JP2023075272A (ja) 2017-01-31 2023-03-14 ガン治療

Country Status (7)

Country Link
US (2) US20200197335A1 (enExample)
EP (1) EP3576746A4 (enExample)
JP (2) JP2020515523A (enExample)
CN (1) CN110494142A (enExample)
AU (2) AU2018215857A1 (enExample)
CA (1) CA3051840A1 (enExample)
WO (1) WO2018143826A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020027665A1 (en) * 2018-07-30 2020-02-06 Gillies Mcindoe Research Institute Novel pharmaceutical compositions for cancer therapy
WO2020135920A1 (en) * 2018-12-28 2020-07-02 Université Libre de Bruxelles Kit for inhaled chemotherapy, and treatment of lung cancer with said kit
US20230090708A1 (en) * 2020-01-29 2023-03-23 Massey Ventures Limited Methods and compositions for the treatment of hemangioma
US20240180852A1 (en) * 2021-03-03 2024-06-06 Signpath Pharma, Inc. Treatment for malignant pleural effusion in humans
CN113069443A (zh) * 2021-04-12 2021-07-06 四川大学 奈必洛尔在制备预防和/或治疗口腔白斑及口腔鳞状细胞癌的药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070093457A1 (en) * 2004-02-11 2007-04-26 Nadir Arber Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid
WO2016024870A1 (en) * 2014-08-12 2016-02-18 Gillies Mcindoe Research Institute Cancer diagnosis and therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3164121A4 (en) * 2014-07-01 2018-06-13 Vicus Therapeutics, LLC Combination drug therapies for cancer and methods of making and using them
WO2016054511A1 (en) * 2014-10-02 2016-04-07 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of aging-associated dysfunction of stem cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070093457A1 (en) * 2004-02-11 2007-04-26 Nadir Arber Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid
WO2016024870A1 (en) * 2014-08-12 2016-02-18 Gillies Mcindoe Research Institute Cancer diagnosis and therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH AND TREATMENT, vol. 46, no. 1, JPN6022001653, 2014, pages 2 - 18, ISSN: 0004920325 *
DRUGS OF TODAY, vol. 50, no. 9, JPN6022001652, 2014, pages 623 - 640, ISSN: 0004920324 *
JOURNAL OF NARA MEDICAL ASSOCIATION, vol. Vol.63, No.5/6, JPN6022001651, 2012, pages 95 - 102, ISSN: 0004920323 *

Also Published As

Publication number Publication date
EP3576746A4 (en) 2020-09-09
AU2024200098A1 (en) 2024-01-25
US20200197335A1 (en) 2020-06-25
AU2018215857A1 (en) 2019-08-15
CN110494142A (zh) 2019-11-22
WO2018143826A1 (en) 2018-08-09
JP2023075272A (ja) 2023-05-30
US20230364037A1 (en) 2023-11-16
EP3576746A1 (en) 2019-12-11
CA3051840A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
US20230364037A1 (en) Cancer therapeutic
CN104519887B (zh) 包含B‑Raf抑制剂、EGFR抑制剂和任选PI3Kα抑制剂的药物组合
JP2020122015A (ja) 併用療法
JP6337170B2 (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
CA2890663A1 (en) Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
EP4570314A2 (en) Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure
AU2016285597A1 (en) Combination of HDAC inhibitor and anti-PD-L1 antibody for treatment of cancer
KR20240104138A (ko) 니로가세스타트를 사용한 조성물 및 치료
US20250090514A1 (en) Method of treating cancer
KR20250013187A (ko) 니로가세스타트를 사용한 치료
WO2020027665A1 (en) Novel pharmaceutical compositions for cancer therapy
WO2024127140A1 (en) Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
NZ796238A (en) Cancer therapeutic
JP2019537614A (ja) 固形腫瘍を治療するための医薬組成物
TW202029961A (zh) Ar拮抗劑聯合parp抑制劑在製備治療前列腺癌的藥物中的用途
US20250120970A1 (en) Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug
EP4522153A1 (en) Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor
TW202435890A (zh) Raf抑制劑及kras g12c抑制劑組合療法
KR20220128984A (ko) sGC 자극제를 사용한 당뇨병성 신장병증의 치료
WO2020205608A1 (en) Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto
Morris et al. Does prescribed medication cause colonic diverticular perforation? A case-control study

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220607

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221115